Anti-factor VIII antibody-producing B cell

Anti-factor VIII antibody-producing B cells are a specialized subpopulation of B lymphocytes that recognize and respond to factor VIII, a clotting factor deficient in hemophilia A. Upon exposure to factor VIII, these B cells can become activated, undergo clonal expansion, class-switch recombination, and differentiate into plasma cells that secrete high-affinity antibodies against factor VIII[2][4][5]. The production of anti-factor VIII antibodies, also known as inhibitors, poses a serious clinical challenge in the management of hemophilia A, as these antibodies neutralize therapeutic factor VIII and render replacement therapy ineffective[1][7][11][13]. The development and persistence of these inhibitor-producing B cells is regulated by multiple factors, including T cell help, cytokines such as B cell-activating factor (BAFF), and immune tolerance mechanisms[1][3][5][7]. Strategies to suppress or eliminate these B cells include immune tolerance induction (repeated high-dose factor VIII administration), B cell-depleting therapies (e.g., rituximab), and modulation of B cell survival pathways (e.g., anti-BAFF therapy)[1][3][7][11]. While not a traditional molecular target (such as a receptor or enzyme), anti-factor VIII antibody-producing B cells are increasingly considered a cellular therapeutic target in hemophilia A and related immune-mediated complications. The name is descriptive of a functional state and specificity rather than a single molecule, so structured therapeutic targeting typically focuses on surface markers (such as CD20, CD19) or survival pathways common to B cell subsets[1][3][7].

Other names

Factor VIII-specific B cellFVIII-specific B cellanti-factor VIII B cell

B cell depletion (e.g., anti-CD20: rituximab) Inhibition of B cell differentiation/survival (e.g., anti-BAFF: belimumab) Immune tolerance induction (high-dose factor VIII therapy)